ArticleJACC. Case reports2025
2-Year Follow-Up of Baroreflex Activation Therapy for Severe Heart Failure With Reduced Ejection Fraction.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBaroreflex activation therapy (BAT) is a novel treatment for heart failure with reduced ejection fraction (HFrEF) in patients who remain symptomatic despite optimal medical therapy (OMT) and who are unsuitable for cardiac resynchronization therapy (CRT). BAT modulates the autonomic nervous system by electrically stimulating carotid baroreceptors, thus potentially improving heart function and symptoms. CASES SUMMARY: Two male HFrEF patients with nonischemic cardiomyopathy, symptomatic (NYHA functional class III) despite OMT, underwent successful BAT implantation. Patient 1, a 41-year-old man with a left ventricular ejection fraction (LVEF) of 34%, and patient 2, a 49-year-old man with an LVEF of 21%, showed significant improvements at 2-year follow-up, including increased LVEF, reduced N-terminal pro-B-type natriuretic peptide, better exercise capacity, and symptomatic relief (NYHA functional class II). Both patients avoided hospital readmissions and had no complications. DISCUSSION: This case series demonstrates BAT's potential for improving clinical outcomes in HFrEF patients ineligible for CRT. Further research is necessary to confirm these findings in larger groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.